Info

34. Stocchi, F.: Int. J. Clin. Pract. 60:215-221, 2006.

35. Olanow, C. W., Watts, R. L., and Koller, W. C.: Neurology 56:S1-S88, 2001.

36. Clarke, C. E., and Guttman, M.: Lancet 360:1767-1769, 2002.

37. Kvernmo, T., Härtter, S., and Burger, E.: Clin. Ther. 28:1065-1078, 2006.

38. Waller, E. A., Kaplan, J., and Heckman, M. G.: Mayo Clin. Proc. 80:1016-1020, 2005.

39. Hagan, J. J., et al.: Trends Pharmacol. Sci. 18:156-163, 1997.

40. Tan, E. K., and Jankovic, J.: Clin. Neuropharmacol. 24:247-253, 2001.

41. Jähnichen, S., Horowski, R., and Pertz, H. H.: Eur. J. Pharmacol. 513:225-228, 2005.

42. Nakatsuka, A., Nagai, M., Yabe, H., et al.: J. Pharmacol. Sci. 100:59-64, 2006.

43. Joyce, J. N., and Millan, M. J.: Curr. Opin. Pharmacol. 7:100-105, 2007.

44. Dooley, M., and Markham, A.: Drugs Aging 12:495-514, 1998.

45. Deleu, D., Northway, M. G., and Hanssens, Y.: Clin. Pharmacokinet. 41:261-309, 2002.

46. Kaye, C. M., and Nicholls, B.: Clin. Pharmacokinet. 39:243-254, 2000.

47. Matheson, A. J., and Spencer, C. M.: Drugs 60:115-137, 2000.

48. Reynolds, N. A., Wellington, K., and Easthope, S. E.: CNS Drugs 19:973-981, 2005.

49. Kreiss, D. S., Bergstrom, D. A., Gonzalez, A. M., et al.: Eur. J. Pharmacol. 277:209-214, 1995.

50. Keating, G. M., and Lyseng-Williamson, K. A.: CNS Drugs 19:165-184, 2005.

51. Gordin, A., Kaakkola, S., and Teräväinen, H.: J. Neural Transm. 111:1343-1363, 2004.

52. Jorga, K., et al.: Br. J. Clin. Pharmacol. 49:39-48, 2000.

53. LeWitt, P. A.: Pharmacotherapy 20:26S-32S, 2000.

54. Allers, K. A., et al.: Exp. Neurol. 191:104-118, 2005.

55. Matsubayashi, H., Swanson, K. L., and Albuquerque, E. X.: J. Pharmacol. Exp. Ther. 281:834-844, 1997.

56. Baldessarini, R. J., and Tarazi, F. I.: Pharmacotherapy of Psychosis and Mania. In Brunton, L. L., Parker, K., and Lazo, J. S. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York, McGraw-Hill, 2006, pp. 429-460.

57. Lewis, D. A., and Lieberman, J. A.: Neuron 28:325-334, 2000.

58. McDonald, C., and Murphy, K. C.: Psychiatr. Clin. North. Am. 26:41-63, 2003.

59. Lewis, D. A., and Levitt, P.: Annual Rev. Neurosci. 25:409-432, 2002.

62. Abi-Dargham, A.: Int. Rev. Neurobiol. 78:133-164, 2007.

63. Seeman, P., and Lee, T.: Science 188:1217-1219, 1975.

65. Abi-Dargham, A., and Laruelle, M.: Eur. Psychiatry 20:15-27, 2005.

66. Davis, K. L., et al.: Am. J. Psychiatry 148:1474-1486, 1991.

67. Lieberman, J. A., Sheitman, B. B., and Kinon, B. J.: Neuropsychopharmacology 17:205-229, 1997.

68. Okubo, Y., Suhara, T., Suzuki, K., et al: Nature 385:634-636, 1997.

69. Frankle, W. G., Lerma, J., and Laruelle, M.: Neuron 39:205-216, 2003.

70. Weinberger, D. R., and Laruelle, M.: Neurochemical and Neuropharmacological Imaging in Schizophrenia. In Davis, K. L., et al. (eds.). Neuropsychopharmacology: Fifth Generation of Progress. Philadelphia, Lippincott, Williams and Wilkins, 2002, pp. 833-855.

71. Stone, J. M., Morrison, P., and Pilowsky, L. S.: J. Psychopharmacol. 21:440-452, 2007.

72. Miyamoto, S., et al.: Therapeutics of Schizophrenia. Neuropsychopharmacology: The Fifth Generation of Progress; Davis, K. L., et al., (eds.). Philadelphia, Lippincott, Williams and Wilkins, 2002, pp. 775-808.

73. Lehmann, H. E., and Ban, T. A.: Can. J. Psychiatry 42:152-162, 1997.

74. Petersen, P. V., et al.: Arzneimittelforschung 8:395-397, 1958.

75. Petersen, P. V., Lassen, N. O., and Holm, T. O.: 2-Chloro-9-(3-dimethylaminopropylidene) thiaxanthene and its amine exchange reactions; (Kefalas A/S). United States, 1964; US 3149103, 6 pp.

77. Froimowitz, M., and Cody, V.: J. Med. Chem. 36:2219-2227, 1993.

78. Feinberg, A. P., and Snyder, S. H.: Proc. Natl. Acad. Sci. U. S. A. 72:1899-1903, 1975.

79. Kaiser, C., Pavloff, A. M. Garvey, E., et al.: J. Med. Chem. 15:665-673, 1972.

80. Horn, A. S., and Snyder, S. H.: Proc. Natl. Acad. Sci. U. S. A. 68:2325-2328, 1971.

81. Grol, C. J., et al.: J. Med. Chem. 25:5-9, 1982.

82. Kaiser, C., Tedeschi, D. H., Fowler, P. J., et al.: J. Med. Chem. 14:179-186, 1971.

83. Gareri, P., et al.: Clin. Drug Investig. 23:287-322, 2003.

84. Belal, F., Hefnawy, M. M., and Aly, F. A.: J. Pharm. Biomed. Anal. 16:369-376, 1997.

85. Shen, W. W.: Biol. Psychiatry 41:814-826, 1997.

86. Fang, J., and Gorrod, J. W.: Cell. Mol. Neurobiol. 19:491-510, 1999.

87. Chetty, M., et al.: Eur. Neuropsychopharmacol. 6:85-91, 1996.

88. Terry, A. V., Gearhart, D. A., Mahadik, S. P., et al.: Neuroscience 136:519-529, 2005.

89. Wishart, D. S., Knox, C., Guo, A. C., et al.: Nucleic Acids Res. 34:D668-D672, 2006.

90. IPCS Intox Databank, 2007, http://www.intox.org/databank/ index.htm.

91. Mula, M., and Monaco, F.: Clin. Neuropharmacol. 25:280-289, 2002.

92. Janssen, P. A. J.: Haloperidol and related Butyrophenones. In Gordon, M. (ed.). Psychopharmacological Agents. Philadelphia, Academic Press, 1967, pp. 199-248.

93. Sikazwe, D. M. N., Li, S., Mardenborough, L., et al.: Bioorg. Med. Chem. Lett. 14:5739-5742, 2004.

94. Ravina, E., and Masaguer, C. F.: Curr. Med. Chem. 1:43-62, 2001.

95. Fang, J., McKay, G., Song, J., et al.: Drug Metab. Dispos. 29:1638-1643, 2001.

96. Beresford, R., and Ward, A.: Drugs 33:31-49, 1987.

97. Forsman, A., et al.: Curr. Ther. Res. 21:606-617, 1977.

98. Glue, P., and Banfield, C.: Human Psychopharmacol. 11:97-114, 1996.

99. Desta, Z., Kerbusch, T., Soukhova, N., et al.: J. Pharmacol. Exp. Ther. 285:428-437, 1998.

100. Matsui-Sakata, A., Ohtani, H., and Sawada, Y.: Drug Metab. Pharmacokinet. 20:368-378, 2005.

101. Kapur, S., and Seeman, P.: Am. J. Psychiatry 158:360-369, 2001.

102. Weiner, D. M., Burstein, E. S., Nash, N., et al.: J. Pharmacol. Exp. Ther. 299:268-276, 2001.

103. Roth, B. L., Sheffler, D., and Potkin, S. G.: Clin. Neurosci. Res. 3:108-117, 2003.

104. Dean, B., and Scarr, E.: Curr. Drug Targets CNS Neurol. Disord. 3: 217-225, 2004.

105. Horacek, J., Bubenikova-Valesova, V., Kopecek, M., et al.: CNS Drugs 20:389-409, 2006.

106. Kiss, B., and Bitter, I.: Structural Analogues of Clozapine. Analogue-Based Drug Discovery, 1st ed. In Fisher, J., and Ganellin, CR. (eds.). Research Triangle Park, Wiley-VCH, 2006, pp. 297-314.

107. Raggi, M. A., et al.: Curr. Med. Chem. 11:279-296, 2004.

108. Meltzer, H. Y.: Psychopharmacology 99:S18-S27, 1989. Psychopharmacology (Berl) 163:1-3, 2002.

109. Fang, J., et al.: Naunyn Schmiedebergs Arch. Pharmacol. 358:592-599, 1998.

110. Burstein, E. S., Ma, J., Wong, S., et al.: J. Pharmacol. Exp. Ther. 315:1278-1287, 2005.

111. Williams, D. P., et al.: J. Pharmacol. Exp. Ther. 283:1375-1382, 1997.

112. Kassahun, K., Mattiuz, E., Nyhart, E., Jr., et al.: Drug Metab. Dispos. 25:81-93, 1997.

113. Kassahun, K., et al.: Drug Metab. Dispos. 26:848-855, 1998.

114. Bymaster, F. P., and Felder, C. C.: Mol. Psychiatry 7:S57-S63, 2002.

115. Lambert, M. T., et al.: Prog. Neuropsychopharmacol. Biol. Psychiatry 30:919-923, 2006.

116. Moisan, J., et al.: Pharmacoepidemiol. Drug Saf. 14:427-436, 2005.

117. DeVane, C. L., and Nemeroff, C. B.: Clin. Pharmacokinet. 40:509-522, 2001.

118. Grimm, S. W., et al.: Br. J. Clin. Pharmacol. 61:58-69, 2006.

119. Nemeroff, C. B., Kinkead, B., and Goldstein, J.: J. Clin. Psychiatry 63:5-11, 2002.

120. Newman-Tancredi, et al.: Eur. J. Pharmacol. 428:177-184, 2001.

121. Berecz, R., Dorado, P., De La Rubia, A., et al.: Curr. Drug Targets 5:573-579, 2004.

122. Mahatthanatrakul, W., Dorado, P., De La Rubia, A., et al.: J. Clin. Pharm. Ther. 32:161-167, 2007.

123. Fang, J., Bourin, M., and Baker, G. B.: Naunyn Schmiedebergs Arch. Pharmacol. 359:147-151, 1999.

124. Yasui-Furukori, N., Hidestrand, M., Spina, E., et al.: Drug Metab. Dispos. 29:1263-1268, 2001.

125. Bork, J. A., et al.: J. Clin. Psychiatry 60:469-476, 1999.

126. Nyberg, S., et al.: Am. J. Psychiatry 156:869-875, 1999.

127. Garver, D. L.: Curr. Drug Targets 7:1205-1215, 2006.

128. Harrison, T. S., and Perry, C. M.: Drugs 64:1715-1736, 2004.

129. Winans, E.: Am. J. Health Syst. Pharm. 60:2437-2445, 2003.

130. Jordan, S., Koprivica, V., Chen, R., et al.: Eur. J. Pharmacol. 441:137-140, 2002.

131. Wood, M. D., Scott, C., Clarke, K., et al.: Eur. J. Pharmacol. 546:88-94, 2006.

132. Potkin, S. G., Saha, A. R., Kujawa, M. J., et al.: Arch. Gen. Psychiatry 60:681-690, 2003.

133. Obach, R. S., and Walsky, R. L.: J. Clin. Psychopharmacol. 25:605-608, 2005.

134. Beedham, C., Miceli, J. J., and Obach, R. S.: J. Clin. Psychopharmacol. 23:229-232, 2003.

135. Stimmel, G. L., Gutierrez, M. A., and Lee, V.: Clin. Ther. 24:21-37, 2002.

136. Beal, M. F.: J. Bioenerg. Biomembr. 36:381-386, 2004.

137. Shults, C. W., Haas, R. H., and Beal, M. F.: Biofactors 9:267-272, 1999.

138. Bonuccelli, U., and Del Dotto, P.: Neurology 67(7 Suppl 2):S30-S38, 2006.

139. Djaldetti, R., and Melamed, E.: J. Neurol. 249 Suppl 2:II30-II35, 2002.

141. Gash, D. M., Zhang, Z., Ovadia, A., et al.: Nature 380:252-255, 1996.

142. Kristiansen, L. V., Huerta, I., Beneyto, M., et al.: NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7:48-55, 2007.

Was this article helpful?

0 0
Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment